Checkpoint inhibitor/bispecific antibody combo: REGN2810 and REGN1979 in B-lymphoid malignancies

Checkpoint inhibitor/bispecific antibody combo: REGN2810 and REGN1979 in B-lymphoid malignancies

VJHemOnc

2 years
158 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
Report 0 0
Category:
Description:
Immune checkpoint inhibitors and T-cell engaging bi-specific antibodies have shown promising activity against lymphoid malignancies. In this interview, Anthony Mato, MD, MSCE, of the University of Pennsylvania, Philadelphia, PA, discusses the open-label, multicenter study of REGN2810 alone or in combination with REGN1979 in patients with B-lymphoid malignancies (NCT02651662). This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Up Next Autoplay